1. Preliminary study of combination treatment of immune checkpoint inhibitors and modulated electro-hyperthermia in recurrent gynecologic malignancies.
- Author
-
Min Chul Choi, Jihyun Moon, Chan Lee, Sang Geun Jung, and Hyun Park
- Subjects
IMMUNE checkpoint inhibitors ,TERMINATION of treatment ,APOPTOSIS ,GYNECOLOGIC cancer ,UTERINE cancer - Abstract
Objective: We investigated the treatment outcomes of immune checkpoint inhibitor (ICI) with modulated electro-hyperthermia (mEHT) in patients with recurrent gynecologic cancers. Methods: We retrospectively reviewed the medical records of nine patients who underwent ICI treatment combined with mEHT for recurrent gynecologic cancers at single institution. Results: The median age of the patients was 48 years (range, 44-63). Two, 4, and 3 patients presented with cervical, ovarian, and uterine cancers, respectively. The median line of prior chemotherapy was 2 (1-5). Mismatch repair deficient or high microsatellite instable tumor was found in 2 patients, and seven patients' tumor exhibited more than 1 point at combined positive score in programmed cell death ligand-1. Eight patients received pembrolizumab and one received nivolumab with mEHT every two or three times a week in accordance with the timing of the ICI administration. As treatment results, 1 (11%) and 2 (22%) patients showed complete response and partial response, respectively, with a median progression-free survival of 6.5 months (range, 0.7-44.1). Two experienced stable disease and four progressions were observed. The median overall survival was 16.7 months (range, 1.3-44.1). There was no treatment discontinuation due to adverse events or treatment related death. Conclusion: This small number study showed that ICI with mEHT for recurrent gynecologic cancers could be feasible without severe adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF